Impact of Brokerage Rating on Sucampo Pharmaceuticals, Inc.(SCMP)

Many Sucampo Pharmaceuticals, Inc.(SCMP) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Sucampo Pharmaceuticals was Upgraded by Mizuho on Dec 22, 2016 to Buy, Price Target of the shares are set at $16.

Company has reported several Insider transactions to the SEC, on Nov 30, 2016, Peter Greenleaf (CEO) sold 200,000 shares at 16.83 per share price.On Nov 30, 2016, Daniel P Getman (director) sold 20,000 shares at 16.82 per share price.On Nov 28, 2016, Matthias Alder (EVP, Bus. Dev.&Lic, G.C. &Sec.) sold 150,000 shares at 16.13 per share price.

Sucampo Pharmaceuticals Last issued its quarterly earnings results on Nov 9, 2016. The company reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $0.27. The company had revenue of $57.90 million for the quarter, compared to analysts expectations of $51.30 million. The companys revenue was up 73.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.16 EPS.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1.67 by 6 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares are expected to touch $20.33 in the short term. This short term price target has been shared by 6 analysts. However, the standard deviation of short term price estimate has been valued at 6.53. The target price could hit $29 on the higher end and $14 on the lower end.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rose 2.17% or 0.25 points on Tuesday and made its way into the gainers of the day. After trading began at $11.5 the stock was seen hitting $11.85 as a peak level and $11.45 as the lowest level. The stock ended up at $11.75. The daily volume was measured at 613,715 shares. The 52-week high of the share price is $17.545 and the 52-week low is $9.59. The company has a market cap of $539 million.

Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.

Sucampo

Share this post

Post Comment